We investigated the clinical efficacy of moxalactam for treatment of a variety of infectious disorders in 50 patients (38 males and 12 females). Patient ages ranged from 8 days to 98 years, with a median of 66 years. Infectious disorders were confirmed by isolation of etiological bacteria in all patients. Thirty-eight patients had gram-negative bacillary disease, nine had pneumococcal infection, and three had disorders caused by staphylococci or streptococci. Twenty-three patients had pneumonia, 17 had bacteremic diseases other than pneumonia, and 10 had miscellaneous infectious diseases. 
Moxalactam disodium (LY127935) is a new semisynthetic beta-lactam antimicrobial agent. It is a 1-oxa-beta-lactam antibiotic; an oxygen molecule has been substituted for sulfur in the cephem nucleus. A previous communication from this laboratory reported the results of in vitro susceptibility testing with this agent against a large number of clinical isolates of gram-negative bacilli (6) . During the last 2 years, a trial of the efficacy of moxalactam has been carried out in patients at this institution; the results are described here.
MATERIALS AND MlEHODS
Patients who were hospitalized at The University Hospital of the University of Alabama Medical Center and at the Birmingham Veteran's Administration Medical Center, Birmingham, Ala., were available for study (one patient was treated at an outside hospital). In most instances, medical house staff serving at these institutions identified patients suspected of fulfilling criteria for entry into the study. The patients were then interviewed by one of us (W.K.L.); if criteria were met, informed consent was solicited and obtained. This was not a controlled study; patients were selected and treated consecutively, and no other antimicrobial regimen was used. Underlying diseases were determined by exaniination of the patients and their medical records.
All of the following criteria were necessary for enrollment in the study: (i) suspected bacterial infection and anticipated isolation of the etiological microorganism(s) from either blood, spinal fluid, or other normally sterile fluid or from inflammatory exudate; (ii) no prior antimicrobial agent(s) effective against the etiological bacteria; (iii) no history of allergy to ceph-88 alosporin-type agents and no history of an immediate hypersensitivity reaction to penicillins; (iv) nonpregnant female; (v) no identifiable risk of life-threatening pseudomonas disease (for example, patients with acute leukemia and granulocytopenia); (vi) no evidence of prosthetic valve endocarditis; and (vii) no evidence of central nervous system infectious disease (patient 49 represents an exception; see below). For retention in the study, the etiological bacteria had to be isolated, identified, and susceptible to moxalactam by disk diffusion testing. Initially, bacteria exhibiting zone sizes of 18 mm or greater were considered susceptible. Later, during the course of the study, criteria were changed by the manufacturer, therefore, a zone size of-23 mm was used to define susceptible organi ms, and a zone of 15 to Table 2 summarizes the outcome of 23 patients with pneumonia. All patients were cured clinically. Two of the patients (4 and 37) had bacteremic disease, whereas the remainder were diagnosed by sputum culture. Transtracheal aspirations were not performed. The etiological microorganisms of nonpneumococcal pneumonias were determined by blood culture in one patient, by pure culture from sputum in five patients, by abundant growth from one sputum culture in four patients, and by abundant growth from more than one sputum culture in four patients. Follow-up sputum cultures were obtained in 21 patients, and in 19 the suspected etiological microorganisms were eliminated. Two patients were considered bacteriological failures. Despite clinical and radiological improvement in patient 4, bronchial washings and sputum continued to grow Streptococcus pneumoniae susceptible to moxalactam. The blood cultures which were initially positive for that microorganism were subsequently sterile. Patient 47, who developed gram-negative pneumonia after admission for respiratory failure, improved clinically and radiologically during treatment but continued to produce small amounts of sputum from which Proteus mirabilis was recovered after discontinuation of moxalactam.
Seventeen patients with bacteremic disorders other than pneumonia were treated with moxalactam, and 16 ( Table 3 ). Bacteremic illnesses included pyelonephritis in eight patients and one patient each with intraabdominal abscess, mediastinitis, thermal injury, decubitus ulcer, hepatic abscess, perinephric abscess, infective endocarditis, ulcerating colonic carcinoma, and septic phlebitis. Patient 15, who was admitted with "locked-in" syndrome after cerebral infarction, developed urinary tract infection and bacteremia with Pseudomonas aeruginosa. Both blood and urine cultures became sterile during moxalactam therapy, but on the 11th day of treatment, while ostensibly improving, the patient died suddenly. No post-mortem examination was performed. In all other patients in this group, follow-up cultures were obtained which documented eradication of the etiological microorganism in each. Table 4 provides information on the patients with infectious disorders without documented bacteremia. In all patients except 25 and 31, the suspected etiological microorganisms were cultured on more than one occasion, and often on several cultures during extended periods of time. Patients 28 and 31, with nonbacteremic urinary tract infection, were cured. All four patients with soft tissue infections (20, 23, 25, and 44) were cured bacteriologically and clinically. Patients 23 and 44 required surgical intervention, whereas patients 20 and 25 received skin grafts to the involved sites after eradication of their infections.
Three patients were treated with moxalactam for osteomyelitis (16, 27 , and 42), and one infant (49) required the drug for treatment of gramnegative meningitis (Table 4 
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Eosinophilia of 8 and 11%, respectively, was noted in two patients. Patient 27 developed drug fever on the 11th day of therapy, and fever resolved after discontinuation of drug 3 days later. Patient 31 developed pruritus, without eosinophilia or rash, which responded partially to an oral antihistamine. However, the pruritus did not fully resolve until 1 month after completion of antibiotic therapy.
Patient 42 experienced mild anorexia, which improved rapidly after moxalactam was stopped. One patient with mild chronic renal insufficiency experienced a decrease in hemoglobin, from 10.4 to 8.6 g/100 ml, during 9 (10, 12, 19) . In addition, they broaden the spectrum ofcephalosporins to include P. aeruginosa, serratia, and some acinetobacter strains. These third-generation cephalosporins are, in general, less active than penicillin G and semisynthetic penicillins against gram-positive microorganisms such as staphylococci and streptococci (18, 19) . However, disease caused by these latter microorganisms has been sucessfully treated with moxalactam. Moxalactam has been shown to be effective in vitro against multiply resistant gram-negative bacilli (10) and against anaerobic microorganisms such as Bacteroides fragilis and Clostridium perfringens (4, 8, 12) . It is also active against strains of Legionella (7). Moxalactam is not active against enterococci (11) . A previous report from this laboratory (6) (15) , and abnornal liver function tests were present in 14 to 24%. In this series, moxalactam administration was associated with no instance of phlebitis, whereas eosinophila and abnormal liver function tests were found in 4 and 22% of patients, respectively. Importantly, moxalactam therapy had to be discontinued in only one patient.
The broad antibacterial spectrum of moxalactam, its relative lack of toxicity, and the encouraging results of clinical trials such as this one will probably result in widespread consideration of the agent once it is released for general use. An important clinical decision in the management of patients with suspected or proven bacterial disorders will be whether or not moxalactam alone is adequate therapy before the infecting bacteria are isolated and identified. Patients who were granulocytopenic and therefore at risk for life-threatening disease caused by P. aeruginosa were not recruited into this clinical trial. Thirty percent of the strains of P. aeruginosa from this institution have MICs of moxalactam greater than 32 ,tg/ml. The number of patients in this series with infections involving P. aeruginosa is small, and several of these required treatment with aminoglycosides due to resistance to moxalactam. As a result, we do not feel justified in using moxalactam alone in granulocytopenic patients, nor would we recommend the use of moxalactam alone for other patients likely to have pseudomonas disease. We did not investigate in vitro or in vivo synergism or antagonism between moxalactam and other antimicrobial agents, such as the aminoglycosides. Although the combination of moxalactam and an aminoglycoside may be quite active against strains of P. aeruginosa with MICs greater than 32 yg/ml, until in vitro and in vivo data are available, "standard" regimens against pseu-domonas such as carbenicillin or ticarciliin combined with gentamicin or tobramycin should be used.
We also advise that moxalactam therapy not be used for patients with serious intravascular infections caused by gram-positive microorganisms. There is no good clinical evidence presently available to indicate how effective moxalactam will be in this group. Patients with prosthetic valve endocarditis caused by Staphylococcus epidermidis or S. aureus are an especially vexing problem and should not routinely be treated with moxalactam until its efficacy in these disorders has been proven.
In contrast, moxalactam may prove very useful in bacterial disorders caused by more than one species. Cellulitis and intraabdominal infections due to aerobic and anaerobic bacteria should respond well to this agent alone, eliminating the necessity for aminoglycosides to treat reigstant aerobic gram-negative bacilli and clindamycin or chloramphenicol to treat Bacteroides fragilis.
Many of the patients described in this report had disorders caused by bacteria which are susceptible to older and clinically proven agents. Penicillin G remains the drug of choice for pneumococcal disease, and urinary tract infection caused by "susceptible" E. coli can be managed with ampicillin. Moxalactam will probably be most valuable if clinicians restrict its use to initial therapy of bacterial disorders due to potentially resistant microorganisms and for follow-up treatment of difficult disorders such as pneumonia, osteomyelitis, and intraabdominal disease caused by resistant or multiple bacteria.
